EP4704841A1 - Imlunestrant ou sels de celui-ci destinés à être utilisés dans le traitement et la prévention de métastases du système nerveux central (snc) chez des sujets ayant un cancer du sein er+ - Google Patents

Imlunestrant ou sels de celui-ci destinés à être utilisés dans le traitement et la prévention de métastases du système nerveux central (snc) chez des sujets ayant un cancer du sein er+

Info

Publication number
EP4704841A1
EP4704841A1 EP24728819.4A EP24728819A EP4704841A1 EP 4704841 A1 EP4704841 A1 EP 4704841A1 EP 24728819 A EP24728819 A EP 24728819A EP 4704841 A1 EP4704841 A1 EP 4704841A1
Authority
EP
European Patent Office
Prior art keywords
imlunestrant
pharmaceutically acceptable
acceptable salt
subject
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24728819.4A
Other languages
German (de)
English (en)
Inventor
Matthew James VANDE KOPPLE
Andrew Roy CAPEN
Mark CASTANARES
Michele Suzanne DOWLESS
Xueqian Gong
Lysiane HUBER
Anke Klippel-Giese
Loredana PUCA
Vivian RODRIGUEZ CRUZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP4704841A1 publication Critical patent/EP4704841A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des procédés comprenant l'imlunestrant d'un sel pharmaceutiquement acceptable de celui-ci pour le traitement et la prévention de métastases cérébrales. L'invention concerne de telles compositions et de tels procédés, pour le traitement et/ou la prévention de métastases cérébrales chez un sujet souffrant d'un cancer du sein ER +.
EP24728819.4A 2023-05-05 2024-05-02 Imlunestrant ou sels de celui-ci destinés à être utilisés dans le traitement et la prévention de métastases du système nerveux central (snc) chez des sujets ayant un cancer du sein er+ Pending EP4704841A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363500437P 2023-05-05 2023-05-05
PCT/US2024/027427 WO2024233256A1 (fr) 2023-05-05 2024-05-02 Imlunestrant ou sels de celui-ci destinés à être utilisés dans le traitement et la prévention de métastases du système nerveux central (snc) chez des sujets ayant un cancer du sein er+

Publications (1)

Publication Number Publication Date
EP4704841A1 true EP4704841A1 (fr) 2026-03-11

Family

ID=91274562

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24728819.4A Pending EP4704841A1 (fr) 2023-05-05 2024-05-02 Imlunestrant ou sels de celui-ci destinés à être utilisés dans le traitement et la prévention de métastases du système nerveux central (snc) chez des sujets ayant un cancer du sein er+

Country Status (7)

Country Link
EP (1) EP4704841A1 (fr)
KR (1) KR20260005985A (fr)
CN (1) CN121194780A (fr)
AU (1) AU2024268541A1 (fr)
IL (1) IL323913A (fr)
MX (1) MX2025013129A (fr)
WO (1) WO2024233256A1 (fr)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
KR20220079866A (ko) 2019-09-19 2022-06-14 토투스 메디신스 아이엔씨. 치료 접합체
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
AU2021263914A1 (en) 2020-04-29 2022-11-03 D.E. Shaw Research, Llc PI3K-α inhibitors and methods of use thereof
TWI837605B (zh) 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
WO2022198024A1 (fr) 2021-03-18 2022-09-22 Totus Medicines Inc. Conjugués thérapeutiques
US20230014445A1 (en) 2021-05-03 2023-01-19 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
IL307950A (en) 2021-05-03 2023-12-01 Petra Pharma Corp Allosteric chromanone inhibitors of PHOSPHOINOSITIDE 3-KINASE (PI3K) for the treatment of diseases
MX2023013987A (es) 2021-05-27 2024-02-12 Petra Pharma Corp Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
US20230000876A1 (en) * 2021-06-09 2023-01-05 Nuvation Bio Inc. Treating cancers with a cyclin-dependent kinase inhibitor
WO2022265993A1 (fr) 2021-06-14 2022-12-22 Scorpion Therapeutics, Inc. Dérivés d'urée pouvant être utilisés pour traiter le cancer
AU2022311952A1 (en) 2021-07-13 2024-01-25 Relay Therapeutics, Inc. PI3Kα INHIBITORS AND METHODS OF USE THEREOF
AU2022325819A1 (en) 2021-08-09 2024-02-29 Scorpion Therapeutics, Inc. Compounds that inhibit pi3k isoform alpha and methods for treating cancer
US20250090540A1 (en) 2021-09-10 2025-03-20 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
US20250084048A1 (en) 2021-10-07 2025-03-13 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
WO2023069644A1 (fr) 2021-10-20 2023-04-27 Mekanistic Therapeutics Llc Composés utiles dans la modulation de egfr et pi3k
TW202334136A (zh) 2021-11-03 2023-09-01 美商傳達治療有限公司 PI3Kα抑制劑及其製造與使用方法
EP4426286A4 (fr) 2021-11-03 2025-12-24 Relay Therapeutics Inc Inhibiteurs bifonctionnels de pi3k-alpha et leurs utilisations
WO2023081209A1 (fr) 2021-11-03 2023-05-11 Zeno Management, Inc. Inhibiteurs de pi3k et méthodes de traitement du cancer
WO2023078401A1 (fr) 2021-11-05 2023-05-11 Fochon Biosciences, Ltd. Composés en tant qu'inhibiteurs de protéine kinase
US20250136568A1 (en) 2021-12-08 2025-05-01 Nanjing Zenshine Pharmaceuticals Co., Ltd. Fused heterocyclic compounds as pi3kalpha inhibitors
WO2023159155A1 (fr) 2022-02-18 2023-08-24 Pivalent Therapeutics, Inc. Inhibiteurs de phosphoinositide 3-kinase (pi3k) et leurs utilisations
EP4490158A4 (fr) 2022-03-10 2026-01-07 Curators Of The University Of Missouri The Nouvel inhibiteur de phosphoinositide 3-kinase (pi3k), compositions le comprenant, procédés de fabrication et procédés de traitement d'une maladie
WO2023192416A1 (fr) 2022-03-29 2023-10-05 Prelude Therapeutics, Incorporated Inhibiteurs de pi3k-alpha mutants et leur utilisation en tant que produits pharmaceutiques
CN119301106A (zh) 2022-04-29 2025-01-10 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)的变构苯并吡喃酮抑制剂
WO2023220131A2 (fr) 2022-05-10 2023-11-16 Relay Therapeutics, Inc. INHIBITEURS DE PI3Kα ET LEURS PROCÉDÉS D'UTILISATION
WO2023230262A1 (fr) 2022-05-26 2023-11-30 Synnovation Therapeutics, Inc. Composés tricycliques en tant qu'inhibiteurs de pi3kalpha
CN117362281A (zh) 2022-07-07 2024-01-09 海创药业股份有限公司 一种pi3k抑制剂及其制备方法和用途
WO2024026423A1 (fr) 2022-07-27 2024-02-01 Black Diamond Therapeutics, Inc. Dérivés de quinoléine substitués utiles comme inhibiteurs de pi3k
US20260048045A1 (en) 2022-08-05 2026-02-19 Scorpion Therapeutics, Inc. Pi3k-alpha inhibitors for the treatment of cancer
WO2024054469A1 (fr) 2022-09-08 2024-03-14 Onkure, Inc. Isoquinolones utilisés en tant qu'inhibiteurs de pi3k
WO2024064024A1 (fr) 2022-09-19 2024-03-28 Onkure, Inc. Dérivés de ((4-oxo-3,4-dihydroquinazolin-8-yl)méthyl)amine utilisés en tant qu'inhibiteurs de p13k pour le traitement du cancer
WO2024086664A2 (fr) 2022-10-18 2024-04-25 Totus Medicines Inc. Inhibiteurs covalents de pi3k de type sauvage et mutants et leur méthodes d'utilisation
CN120457127A (zh) 2022-10-20 2025-08-08 麦克尼斯迪克治疗有限公司 用于调节egfr和pi3k的化合物
WO2024086789A2 (fr) 2022-10-20 2024-04-25 Prelude Therapeutics Incorporated Inhibiteurs de pi3k-alpha mutants et leur utilisation en tant que produits pharmaceutiques

Also Published As

Publication number Publication date
IL323913A (en) 2025-12-01
MX2025013129A (es) 2025-12-01
AU2024268541A1 (en) 2025-11-20
KR20260005985A (ko) 2026-01-12
WO2024233256A1 (fr) 2024-11-14
CN121194780A (zh) 2025-12-23

Similar Documents

Publication Publication Date Title
US20230210852A1 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
US20230092181A1 (en) Intermittent dosing of mdm2 inhibitor
Ma et al. A phase II trial of neoadjuvant MK-2206, an AKT inhibitor, with anastrozole in clinical stage II or III PIK3CA-mutant ER-positive and HER2-negative breast cancer
JP2022034068A (ja) 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
EP3820874B1 (fr) Agents de dégradation sélectifs du récepteur des oestrogènes
KR20180011780A (ko) 암을 치료하는 방법
US20250319044A1 (en) Methods for treating cancer resistant to cdk4/6 inhibitors
US20240122896A1 (en) Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitor
US20220125777A1 (en) Combination of a cdk inhibitor and a pim inhibitor
EP4704841A1 (fr) Imlunestrant ou sels de celui-ci destinés à être utilisés dans le traitement et la prévention de métastases du système nerveux central (snc) chez des sujets ayant un cancer du sein er+
US20240156800A1 (en) Ep300 degrader and uses thereof in neuroblastoma
KR20070046906A (ko) 위장관 기질적 종양 치료를 위한 미도스타우린의 용도
WO2025201518A1 (fr) Méthodes de traitement de gist résistant à l'itk et déficient en sdh
Gumma et al. Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase–driven non-small cell lung cancer therapy
US20210393651A1 (en) Targeting the oncogenic transcription factor stat5 with mineralocorticoid analogues
HK40041681A (en) Selective estrogen receptor degraders
HK40041681B (en) Selective estrogen receptor degraders
HK1231740B (en) Intermittent dosing of mdm2 inhibitor
HK1231740A1 (en) Intermittent dosing of mdm2 inhibitor

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR